| Max E Meschberger, LMLP, LCP, LCMFT | |
|
1145 E Kansas Plz, Garden City, KS 67846-5870 | |
| (620) 275-0625 | |
| (620) 275-7908 |
| Full Name | Max E Meschberger |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 1145 E Kansas Plz, Garden City, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346290137 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Max E Meschberger, LMLP, LCP, LCMFT 1145 E Kansas Plz, Garden City, KS 67846-5870 Ph: (620) 275-0625 | Max E Meschberger, LMLP, LCP, LCMFT 1145 E Kansas Plz, Garden City, KS 67846-5870 Ph: (620) 275-0625 |
News Archive
Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).
Brazil, Russia, India and China, collectively known as BRIC, have reached an agreement to promote global food security, the Moscow Times reports (Anishyuk, 3/29).
The new UK alcohol strategy includes a plan to ensure that General Practitioners (GPs) advise heavy drinkers to cut down.
According to a research conducted at the University of Jyväskylä, estrogen acts as a regulator of muscle energy metabolism and muscle cell viability. Menopause leads to the cessation of ovarian estrogen production concurrent to the deterioration of muscle function.
Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.
› Verified 6 days ago